Lantus is one of the world's best selling drugs, clocking $8 billion per year in revenue, and a cornerstone of Sanofi's (NYSE: SNY) business. Unfortunately for investors in the French pharma, that flagship product is soon to be under attack from a generic biosimilar version from Eli Lilly (NYSE: LLY) and Boehringer Ingelhiem. The CHMP recommended European approval for Abasria, with a a likely "yes" nod from regulators in the coming months.
Sanofi isn't taking the threat to its diabetes business laying down. It has a next generation insulin called Toujeo on the way that looks to improve on Lantus. The company also recently signed a deal with Medtronic (NYSE: MDT) to develop new combined drug and device treatments and offer care management services for the disease.
In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, discuss the news of the Medtronic and Sanofi deal, and what it all means for investors.
